Effects Of Zoledronic Acid On Bone Mineral Density Around Prostheses After Primary Total Hip Arthroplasty In Females With Postmenopausal Osteoporosis

Objective To investigate the effect of zoledronic acid on periprosthetic bone mineral density(BMD)after primary total hip arthroplasty in females with postmenopausal osteoporosis.Methods From November 2015 to April 2016,32 female patients who met the inclusion criteria were randomized into two groups: a control group and a zoledronic acid group.At 1 week,3,6,and 12 months after operation BMD was obtained through Dual Energy X-ray Absorptiometry(DEXA)and before the operation and at 3,6,and 12 months after the operation levels of bone metabolism markers were obtained by serum examination.Results Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1,4,6,and 7,at 6 months and in zones 1,2,4,6,and 7 at 12 months after the operation.The levels of bone-resorption marker(?-CTX)were significantly lower in the ZOL group than in the control group at 3,6,and 12 months after operation.The differences from baseline in the levels of bone-formation marker(TP1NP)were statistically significant differences only at 12 months after the operation.Conclusion Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis.